CY1107264T1 - Αποτελεσματα καταστολης ανοσοποιησης των παραγωγων pteridine - Google Patents

Αποτελεσματα καταστολης ανοσοποιησης των παραγωγων pteridine

Info

Publication number
CY1107264T1
CY1107264T1 CY20081100034T CY081100034T CY1107264T1 CY 1107264 T1 CY1107264 T1 CY 1107264T1 CY 20081100034 T CY20081100034 T CY 20081100034T CY 081100034 T CY081100034 T CY 081100034T CY 1107264 T1 CY1107264 T1 CY 1107264T1
Authority
CY
Cyprus
Prior art keywords
disorders
useful
pteridine
producers
results
Prior art date
Application number
CY20081100034T
Other languages
English (en)
Inventor
Mark Jozef Albert Waer
Piet André Maurits Maria HERDEWIJN
Wolfgang Eugen Pfleiderer
Arnaud Didier Marie Marchand
Jonghe Steven Cesar Alfons De
Original Assignee
4 Aza Ip Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/651,604 external-priority patent/US7276506B2/en
Priority claimed from GB0408955A external-priority patent/GB2413324A/en
Application filed by 4 Aza Ip Nv filed Critical 4 Aza Ip Nv
Publication of CY1107264T1 publication Critical patent/CY1107264T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η εφεύρεση αφορά μία φαρμακευτική σύνθεση δια την θεραπευτική αγωγή αυτοανοσοποιητικών παθήσεων ή δια την θεραπευτική αγωγή και / ή την πρόληψη απορρίψεων μοσχεύματος και / ή δια την θεραπευτική αγωγή φλογιστικών ασθενειών, η οποία περιλαμβάνει ως δραστική ουσία τουλάχιστον ένα παράγωγο πτεριδίνης που έχει το γενικό τύπο (Ι). Η εφεύρεση αφορά περαιτέρω μία ένωση, η οποία έχει τον αναφερθέντα γενικό τύπο και την χρησιμοποίηση μιας ενώσεως ως φαρμάκου και την παρασκευή ενός φαρμάκου δια την θεραπευτική αγωγή αυτοανοσοποιητικών παθήσεων δια την πρόληψη απορρίψεων μοσχεύματος και δια την θεραπευτικήν αγωγή φλογιστικών ασθενών.
CY20081100034T 2003-08-29 2008-01-10 Αποτελεσματα καταστολης ανοσοποιησης των παραγωγων pteridine CY1107264T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/651,604 US7276506B2 (en) 1998-12-28 2003-08-29 Immunosuppressive effects of pteridine derivatives
GB0408955A GB2413324A (en) 2004-04-22 2004-04-22 Pharmaceutically active pteridine derivatives
EP04761485A EP1658081B1 (en) 2003-08-29 2004-08-27 Immunosuppressive effects of pteridine derivatives

Publications (1)

Publication Number Publication Date
CY1107264T1 true CY1107264T1 (el) 2012-11-21

Family

ID=34276842

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100034T CY1107264T1 (el) 2003-08-29 2008-01-10 Αποτελεσματα καταστολης ανοσοποιησης των παραγωγων pteridine

Country Status (10)

Country Link
EP (1) EP1658081B1 (el)
AT (1) ATE376421T1 (el)
AU (1) AU2004267885A1 (el)
CA (1) CA2534151A1 (el)
CY (1) CY1107264T1 (el)
DE (1) DE602004009696T2 (el)
DK (1) DK1658081T3 (el)
ES (1) ES2295897T3 (el)
PL (1) PL1658081T3 (el)
WO (1) WO2005021003A2 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
WO2007024680A1 (en) 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
US20090318456A1 (en) * 2006-07-06 2009-12-24 Gilead Sciences, Inc. Substituted pteridines for the treatment and prevention of viral infections
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US10144736B2 (en) * 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
CN101569617A (zh) * 2009-06-11 2009-11-04 辽宁利锋科技开发有限公司 具有金刚烷结构药物及其衍生物和类似物抗肿瘤新适应症的应用
BR112013030894A2 (pt) 2011-06-01 2016-08-16 Janus Biotherapeutics Inc moduladores do sistema imune
SI3321265T1 (sl) 2015-03-04 2020-07-31 Gilead Sciences, Inc. Spojine 4,6-diamino-pirido(3,2-d)pirimidina in njihova uporaba kot modulatorji toličnih receptorjev
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
MA46093A (fr) 2016-09-02 2021-05-19 Gilead Sciences Inc Composés modulateurs du recepteur de type toll
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN114984019B (zh) * 2022-07-15 2023-08-22 山东中医药大学 一种铁死亡抑制剂化合物及在肝损伤修复领域的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB785353A (en) * 1953-01-30 1957-10-30 Merck & Co Inc Substituted pteridine derivatives
US2940972A (en) * 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US3081230A (en) * 1960-09-08 1963-03-12 Smith Kline French Lab Diuretic and antihypertensive triaminoarylpteridines
US3159628A (en) * 1962-05-28 1964-12-01 Smith Kline French Lab Pteridine-5-oxide derivatives
DE1921308A1 (de) * 1969-04-25 1971-01-07 Boehringer Sohn Ingelheim Herzwirksame Zubereitungen
US3859287A (en) * 1971-05-05 1975-01-07 Walter Wesley Parish Thiopteridines and process for producing same
DE3323932A1 (de) * 1983-07-02 1985-01-10 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-piperazino-pteridine, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel
DE3445298A1 (de) * 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
DD267495A1 (de) * 1987-11-11 1989-05-03 Akad Wissenschaften Ddr Verfahren zur herstellung eines neuen methotrexat-derivates mit verminderter toxizitaet
DE4009941A1 (de) * 1990-03-28 1991-10-02 Thomae Gmbh Dr K Verwendung von pteridinen zur sensibilisierung resistenter plasmodien bei der malaria-chemotherapie und diese verbindungen enthaltende arzneimittel
DE69920757T2 (de) * 1998-12-28 2005-12-15 4 AZA Bioscience N.V. Immunosuppressive wirkungen von pteridinderivaten
US6946465B2 (en) * 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
DE19944767A1 (de) * 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
SE0003828D0 (sv) * 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
DE10202468A1 (de) * 2002-01-23 2004-09-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Pteridinderivate, Verfahren zu deren Herstellung und ihre Verwendung
PT1663244E (pt) * 2003-09-12 2007-11-15 4 Aza Ip Nv Derivados de ptiridina para o tratamento de doenças relacionadas com o tnf-alfa

Also Published As

Publication number Publication date
ATE376421T1 (de) 2007-11-15
ES2295897T3 (es) 2008-04-16
DE602004009696D1 (de) 2007-12-06
PL1658081T3 (pl) 2008-03-31
WO2005021003A3 (en) 2005-06-09
AU2004267885A1 (en) 2005-03-10
DE602004009696T2 (de) 2008-08-28
EP1658081B1 (en) 2007-10-24
DK1658081T3 (da) 2008-02-25
CA2534151A1 (en) 2005-03-10
WO2005021003A2 (en) 2005-03-10
EP1658081A2 (en) 2006-05-24

Similar Documents

Publication Publication Date Title
CY1107264T1 (el) Αποτελεσματα καταστολης ανοσοποιησης των παραγωγων pteridine
PL1673092T3 (pl) Pochodne pterydyny podstawione heterocyklem i ich zastosowanie w leczeniu
ATE422496T1 (de) Als medikamente für die behandlung von autoimmunerkrankungen geeignete substituierte pyridoä2,3-düpyrimidinderivate
WO2006069805A3 (en) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
WO2009003669A3 (en) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
BR0316256A (pt) Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
DK1196397T3 (da) Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
ATE362766T1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
BRPI0418112A (pt) inibidores de p-38 quinase bicìclico heterocìclicos
NO20051966L (no) Nye pyrimidinamidderivater og anvendelse derav
EA200300807A1 (ru) Лечение нарушений центральной нервной системы с использованием антагонистов оксидазы d-аминокислот и d-аспартатоксидазы
WO2005025574A3 (en) PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES.
MX2008016525A (es) Inhibidores heterocíclicos fusionados de d-amino ácido oxidasa.
MX2007000046A (es) Compuestos, composiciones y metodos de imidazolo relacionados para su uso.
ATE277072T1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
ATE403433T1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
MX2007007472A (es) Derivados de triazolona, tetrazolona e imidazolona para uso como antagonista del adrenorreceptor alfa-2c.
DK0700384T3 (da) fremgangsmåde til fremstilling og opløsning af 2-phenyl-3-aminopiperidin
DE60327335D1 (de) Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson
DK1305047T3 (da) Ikke-peptidiske CCR1-receptor-antagonister i kombination med cyclosporin A til behandling af hjertetransplantatafstödning
DE602004010186D1 (de) Diazaspiropiperidinderivate als inhibitoren von glycintransporter 1 und glycintransporter 2
NO20053612L (no) 1,2,4-triaminobenzenderivater nyttige for behandling av forstyrrelser i sentralnervesystemet